North Dakota State Investment Board Makes New $2.76 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

Posted by Francis Steltz on May 19th, 2026

North Dakota State Investment Board bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,579 shares of the biopharmaceutical company’s stock, valued at approximately $2,763,000.

Other hedge funds also recently bought and sold shares of the company. WPG Advisers LLC lifted its holdings in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares during the period. Board of the Pension Protection Fund purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Torren Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $38,000. FNY Investment Advisers LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $38,000. Finally, Oakworth Capital Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 124.0% during the 4th quarter. Oakworth Capital Inc. now owns 56 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the company. Wells Fargo & Company decreased their price objective on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a report on Monday. Evercore increased their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. TD Cowen increased their price objective on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a report on Monday. Finally, Sanford C. Bernstein decreased their price objective on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $800.57.

Check Out Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $629.68 on Tuesday. The firm has a market capitalization of $66.57 billion, a price-to-earnings ratio of 15.34, a price-to-earnings-growth ratio of 1.55 and a beta of 0.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The business has a fifty day moving average of $741.98 and a 200 day moving average of $745.92. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s quarterly revenue was up 19.0% on a year-over-year basis. During the same quarter last year, the business posted $8.22 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.1 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be paid a $0.94 dividend. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Negative Sentiment: Regeneron’s Phase 3 melanoma trial did not show statistically significant improvement on its main goal, disappointing expectations for a key cancer drug candidate. Reuters article
Negative Sentiment: The trial failure triggered a wave of analyst caution and multiple price target cuts, reflecting reduced confidence in near-term pipeline upside. Proactive Investors article
Negative Sentiment: Law firms have started investigating whether Regeneron and its executives made overly optimistic statements about the melanoma program before the disappointing results were disclosed. PR Newswire article
Neutral Sentiment: Regeneron also announced a strategic collaboration with Parabilis Medicines to develop Antibody-Helicon™ Conjugates, which could broaden its pipeline, but the partnership is still early-stage and carries execution risk. GlobeNewswire article

Insiders Place Their Bets

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This trade represents a 0.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.